Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial

American Heart Journal

Volumn 150, Issue 1, 2005, Pages 79-88

  Ohman, E Magnus ^a,h   Van De Werf, Frans ^b   Antman, Elliott M ^c   Califf, Robert M ^d   De Lemos, James A ^e   Gibson, C Michael ^f   Oliverio, Renee L ^d   Harrelson, Lynn ^d   McCabe, Carolyn ^f   DiBattiste, Peter ^g   Braunwald, Eugene ^f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h CB 7075 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; TENECTEPLASE; TIROFIBAN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE;

EID: 19944426630     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.01.007     Document Type: Article

References (23)

1. E.M. Antman, R.P. Giugliano, and C.M. Gibson Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial Circulation 99 1999 2720 2732
2. The SPEED Study Group Trial of abciximab with and without low-dose reteplase for acute myocardial infarction Circulation 101 2000 2788 2794
3. S.J. Brener, U. Zeymer, and A.A. Adgey Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial J Am Coll Cardiol 39 2002 377 386
4. R.P. Giugliano, M.T. Roe, and R.A. Harrington Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the INTEGRIlin and Tenecteplase in acute myocardial Infarction (INTEGRITI) phase II angiographic trial J Am Coll Cardiol 41 2003 1251 1260
5. E.M. Antman, H.W. Louwerenburg, and H.F. Baars Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis In Myocardial Infarction (TIMI) 23 Trial Circulation 105 2002 1642 1649
6. J.A. de Lemos, E.M. Antman, and C.M. Gibson Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial Circulation 101 2000 239 243
7. J.H. Chesebro, G. Knatterud, and R. Roberts Thrombolysis In Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge Circulation 76 1987 142 154
8. C.M. Gibson, C.P. Cannon, and W.L. Daley TIMI frame count: a quantitative method of assessing coronary artery flow Circulation 93 1996 879 888
9. E.G. Bovill, M.L. Terrin, and D.C. Stump Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction Ann. Intern. Med. 115 1991 256 265
10. C.P. Cannon, C.M. Gibson, and C.H. McCabe TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial Circulation 98 1998 2805 2814
11. E.M. Antman, C.M. Gibson, and J.A. de Lemos Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14 Eur Heart J 21 2000 1944 1953
12. D.J. Schneider, P.B. Tracy, and K.G. Mann Differential effects of anticoagulants on the activation of platelets ex vivo Circulation 96 1997 2877 2883
13. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1997 1488 1494
14. S.S. Kabbani, A. Aggarwal, and E.F. Terrien Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions Am J Cardiol 89 2002 647 650
15. The RESTORE Investigators The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
16. E.J. Topol, D.J. Moliterno, and H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
17. S.R. Steinhubl, J.D. Talley, and G.A. Braden Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study Circulation 103 2001 2572 2878
18. D.J. Schneider, H.C. Herrmann, and N. Lakkis Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am J Cardiol 90 2002 1421 1423
19. D.J. Schneider, H.C. Herrmann, and N. Lakkis Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban Am J Cardiol 91 2003 334 336
20. E.J. Topol Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial Lancet 357 2001 1905 1914
21. A.M. Lincoff, R.M. Califf, and F. Van de Werf Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial JAMA 288 2002 2130 2135
22. The ASSENT-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction Lancet 358 2001 605 613
23. P. Armstrong for the ASSENT-3 Investigators ASSENT-3 1-year follow-up Presented at the XXIVth Congress of the European Society of Cardiology, Berlin, September 3 2002